RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
Different minoxidil formulations affect hair growth and side effects. Higher propylene glycol and pH levels improve effectiveness but can cause scalp irritation.
The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.
The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
17-alpha-estradiol may work for hair loss by inhibiting 5-alpha reductase, similar to finasteride. It might lower testosterone in the scalp, reducing DHT conversion.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.
Latanoprost/bimatoprost's effectiveness in hair loss treatment is discussed, with its potential to convert vellus hairs to terminal hairs. It works differently from minoxidil and finasteride, and may be best for hairline application, but is not a replacement for them due to price and mechanism.
Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.
A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.
A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
Mixing RU58841 with a solution for hair loss treatment, with suggestions to use propylene glycol and ethanol instead of k&b solution due to scalp irritation. Recommendations include using ketoconazole shampoo for itchiness and considering oral minoxidil if topical causes irritation.
Musely sells a hair topical solution containing latanoprost, which degrades in 6 weeks, yet they market it as a 3-month supply. Concerns are raised about the product's effectiveness and the company's sales strategy.
The conversation discusses treatments for androgenetic alopecia, focusing on evidence-based supplements to complement finasteride. Suggestions include oral minoxidil, saw palmetto, pumpkin seed oil, tocotrienols, and various other supplements, while emphasizing the importance of scientific backing and cautioning against saw palmetto if already using finasteride.
The post is about whether there is any additional benefit to using alfatradiol or other estrogen treatments for hair loss if someone is already using finasteride, dutasteride, or an androgen receptor inhibitor like RU58841, pyrithione zinc, or fluridil.
Astaxanthin (ASX) is highlighted as a promising supplement for treating hair loss due to its antioxidant properties. It may help with inflammation and oxidative stress, which are linked to hair loss and aging.